Eva Haastrup1, Marianne R S Ifversen2, Carsten Heilmann2, Anne Fischer-Nielsen1. 1. The Cell Therapy Facility, Department of Clinical Immunology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 2. Pediatric and Adolescent Medicine, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND: Depletion of TCRαβ+ T cells and B cells with the CliniMACS Plus® has been used for haploidentical hematopoietic stem cell transplantation for a decade. The depletion procedure is time and labour demanding and with variable reported efficiencies. Recently, an automated procedure was launched for the CliniMACS Prodigy® (Miltenyi Biotec) but reported data are scarce. Here, we report the results of the first ten TCRαβ+ and B cell depletion procedures for clinical use performed at our centre. MATERIALS AND METHODS: All transplants were from a parent to a child. Collection of peripheral blood stem cells was performed after filgrastim mobilisation by use of the Spectra Optia® (TerumoBCT) set on the MNC program. Because of insufficient hematopoietic stem cell mobilisation, 1 donor received additional plerixafor. RESULTS: We performed ten uncomplicated processes with the CliniMACS Prodigy. We found the results of the depletion procedures satisfactory with a median log reduction of TCRαβ+ cells of -4.21 (range -3.98 to -4.74), resulting in a median number of TCRαβ+ cells in the depleted product of 28.6 × 10<sup>3</sup>/kg recipient weight (range 14.9-69.7 × 10<sup>3</sup>/kg). The median CD34 recovery was 83% (range 70-100). To achieve a sufficient number of CD34+ cells, we performed an additional CD34+ enrichment procedure using the CliniMACS Plus for 3 patients. The B cell depletion was slightly less efficient with a median log reduction of -3.72 (range -2.83 to -4.20). CONCLUSION: Overall, we found the TCRαβ and CD19 depletion procedure on the CliniMACS Prodigy easy to handle and reliable, providing reproducible good results.
BACKGROUND: Depletion of TCRαβ+ T cells and B cells with the CliniMACS Plus® has been used for haploidentical hematopoietic stem cell transplantation for a decade. The depletion procedure is time and labour demanding and with variable reported efficiencies. Recently, an automated procedure was launched for the CliniMACS Prodigy® (Miltenyi Biotec) but reported data are scarce. Here, we report the results of the first ten TCRαβ+ and B cell depletion procedures for clinical use performed at our centre. MATERIALS AND METHODS: All transplants were from a parent to a child. Collection of peripheral blood stem cells was performed after filgrastim mobilisation by use of the Spectra Optia® (TerumoBCT) set on the MNC program. Because of insufficient hematopoietic stem cell mobilisation, 1 donor received additional plerixafor. RESULTS: We performed ten uncomplicated processes with the CliniMACS Prodigy. We found the results of the depletion procedures satisfactory with a median log reduction of TCRαβ+ cells of -4.21 (range -3.98 to -4.74), resulting in a median number of TCRαβ+ cells in the depleted product of 28.6 × 10<sup>3</sup>/kg recipient weight (range 14.9-69.7 × 10<sup>3</sup>/kg). The median CD34 recovery was 83% (range 70-100). To achieve a sufficient number of CD34+ cells, we performed an additional CD34+ enrichment procedure using the CliniMACS Plus for 3 patients. The B cell depletion was slightly less efficient with a median log reduction of -3.72 (range -2.83 to -4.20). CONCLUSION: Overall, we found the TCRαβ and CD19 depletion procedure on the CliniMACS Prodigy easy to handle and reliable, providing reproducible good results.
Authors: Sebastian P Haen; Christiane Groh; Michael Schumm; Linus Backert; Markus W Löffler; Birgit Federmann; Christoph Faul; Daniela Dörfel; Wichard Vogel; Rupert Handgretinger; Lothar Kanz; Wolfgang A Bethge Journal: Ann Hematol Date: 2017-02-28 Impact factor: 3.673
Authors: Eun Seok Choi; Ho Joon Im; Hyery Kim; Kyung Nam Koh; Seongsoo Jang; Chan-Jeoung Park; Jong Jin Seo; Ho Ran Park Journal: J Clin Apher Date: 2018-07-03 Impact factor: 2.821
Authors: J R Passweg; H Baldomero; P Bader; C Bonini; R F Duarte; C Dufour; A Gennery; N Kröger; J Kuball; F Lanza; S Montoto; A Nagler; J A Snowden; J Styczynski; M Mohty Journal: Bone Marrow Transplant Date: 2017-03-13 Impact factor: 5.483